| Cardiovascular disease in dialysis patients |
48 |
| SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA |
44 |
| JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial |
38 |
| Chronic inflammation in end-stage renal disease and dialysis |
30 |
| Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper |
29 |
| Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis |
25 |
| Arterial spin labelling MRI to measure renal perfusion: a systematic review and statement paper |
23 |
| Albumin downregulates Klotho in tubular cells |
23 |
| Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey |
22 |
| Renal blood oxygenation level-dependent magnetic resonance imaging to measure renal tissue oxygenation: a statement paper and systematic review |
19 |
| Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease |
18 |
| Health literacy and patient outcomes in chronic kidney disease: a systematic review |
18 |
| Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults |
17 |
| Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents |
17 |
| Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression |
17 |
| Greater fluid overload and lower interdialytic weight gain are independently associated with mortality in a large international hemodialysis population |
16 |
| Effects of erythropoietin on fibroblast growth factor 23 in mice and humans |
16 |
| Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients |
15 |
| Targeting epigenetic DNA and histone modifications to treat kidney disease |
15 |
| The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis |
15 |
| Effects of intradialytic cycling exercise on exercise capacity, quality of life, physical function and cardiovascular measures in adult haemodialysis patients: a systematic review and meta-analysis |
14 |
| Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3-5 |
14 |
| A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation |
14 |
| Expanded haemodialysis: from operational mechanism to clinical results |
14 |
| Magnetic resonance imaging T-1- and T-2-mapping to assess renal structure and function: a systematic review and statement paper |
13 |
| Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study |
13 |
| A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy |
13 |
| Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease |
13 |
| Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications? |
13 |
| Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease |
12 |
| Serum uromodulin-a marker of kidney function and renal parenchymal integrity |
12 |
| Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies |
12 |
| Potential benefits and harms of NADPH oxidase type 4 in the kidneys and cardiovascular system |
12 |
| Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice |
11 |
| Mediterranean diet as the diet of choice for patients with chronic kidney disease |
11 |
| Quality over quantity? Association of skeletal muscle myosteatosis and myofibrosis on physical function in chronic kidney disease |
11 |
| Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study |
11 |
| Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness |
11 |
| Mortality risk in patients on hemodiafiltration versus hemodialysis: a 'real-world' comparison from the DOPPS |
11 |
| Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial |
11 |
| Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy |
11 |
| Large uremic toxins: an unsolved problem in end-stage kidney disease |
11 |
| Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts |
10 |
| Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies |
10 |
| Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? |
10 |
| Perspectives on symptom experiences and symptom reporting among individuals on hemodialysis |
10 |
| Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis |
10 |
| Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients |
10 |
| Mesenchymal stem cells prevent podocyte injury in lupus-prone B6.MRL-Fas(lpr) mice via polarizing macrophage into an anti-inflammatory phenotype |
10 |
| Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes |
10 |
